for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shanghai Pharmaceuticals Holding H Shs

2607.HK

Latest Trade

15.90HKD

Change

0.10(+0.63%)

Volume

2,883,800

Today's Range

15.58

 - 

15.94

52 Week Range

12.82

 - 

19.02

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
15.80
Open
15.58
Volume
2,883,800
3M AVG Volume
54.98
Today's High
15.94
Today's Low
15.58
52 Week High
19.02
52 Week Low
12.82
Shares Out (MIL)
2,842.09
Market Cap (MIL)
61,110.15
Forward P/E
7.01
Dividend (Yield %)
3.62

Next Event

Q4 2021 Shanghai Pharmaceuticals Holding Co Ltd Earnings Release

Latest Developments

更多

Shanghai Pharmaceuticals <2607.Hk> Says 6-Month Net Profit Up 46.1% Y/Y

Shanghai Pharmaceuticals Got Acceptance Of Application For Proposed Non-Public Issuance Of A Shares From CSRC

BlackRock Inc Sold 2.8 Mln H-Shares In Shanghai Pharmaceuticals On May 31 - HKEX Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shanghai Pharmaceuticals Holding H Shs

Shanghai Pharmaceuticals Holding Co Ltd is a China-based company principally engaged in pharmaceutical industry, distribution and retail business. The Company's products include innovative drugs, chemical drugs, traditional Chinese medicines and rare disease drugs. The Company's products are mainly used in the cardiovascular system, digestive tract and metabolism, systemic anti-infection, central nervous system, anti-tumor and immunomodulators, musculoskeletal system and respiratory system. In addition, the Company also provides medical logistics and warehousing services. The Company distributes its products both in the domestic market and to overseas markets.

Industry

Major Drugs

Contact Info

Shanghai Pharmaceutical Mansion

No.200 Taicang Road

SHANGHAI, SHA

200020

China

+86.21.63730908

http://www.sphchina.com/

Executive Leadership

Jun Zhou

Chairman of the Board, Non-Executive Director

Min Zuo

President, Executive Director

Dawei Ge

Vice Chairman of the Board, Non-Executive Director

Bo Shen

Chief Financial Officer, Vice President, Executive Director

Yongzhong Li

Vice President, Executive Director

Key Stats

1.90 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

159.1K

2019

186.6K

2020

191.9K

2021(E)

218.0K
EPS (CNY)

2018

1.370

2019

1.440

2020

1.580

2021(E)

1.876
Price To Earnings (TTM)
6.84
Price To Sales (TTM)
0.23
Price To Book (MRQ)
0.76
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
81.37
LT Debt To Equity (MRQ)
16.91
Return on Investment (TTM)
11.10
Return on Equity (TTM)
4.24

Latest News

Latest News

BRIEF-中国上海医药上半年净利增近五成,带量采购下销售收入仍较快增长

* 公司表示,报告期内虽然部分产品受到国家带量采购政策的影响,但上半年整体销售收入仍实现较快增长,工业大品种逐步消除疫情影响,过亿产品数量再创新高。同时,再度进入全球制药工业50强,排名提升6名,位列第42位。

上海医药向大股东及云南白药增发A股筹近144亿元,后者将成第二大股东

中国医药产业集团--上海医药宣布,分别与上海潭东及云南白药订立认购协议,分别向后者发行非公开发行不超过1.87亿及6.656亿股A股,集资高至143.83亿元人民币。

West China Hospital's COVID-19 vaccine candidate enters mid-stage human trial

An experimental coronavirus vaccine developed by West China Hospital has entered a mid-stage human test, authorities of China's southwestern province of Sichuan said on Tuesday.

UPDATE 2-Drugmakers slash prices to win China's bulk-buy contracts - state media

Drugmakers have slashed prices by up to 95% to win state contracts in China's largest bidding round of its drug procurement programme, state media said on Thursday.

中国第三批国家药品集中采购开标 拟中选产品最高降幅达95%

采购规模达数百亿元人民币的中国第三批国家组织药品集中采购周四在上海开标,并产生拟中选结果。据新华社稍晚报导,本次采购共有189家企业参加,产生拟中选企业125家,拟中选产品191个,拟中选产品平均降价53%,最高降幅95%。

香港新股:中国最大精神疾病类制药公司登场,本周三大IPO筹高至20亿美元

香港本周第三支新股、中国最大精神疾病类制药公司--翰森制药周四登场,与中国船舶租赁和中国东方教育同于下周定价,三大IPO筹高至154亿港元(20亿美元)。

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up